InnoCare Pharma Ltd. (HK:9969) has released an update.
InnoCare Pharma Ltd. reports a significant improvement in financial performance for the first half of 2024, with an 11.2% increase in revenue and a 19.3% rise in gross profit compared to the same period in 2023. This growth is largely attributed to a 30% increase in sales of their drug orelabrutinib, despite a reduction in service revenue. The company also saw an improvement in gross profit margin, now at 85.7%, up 5.8 percentage points from the previous year.
For further insights into HK:9969 stock, check out TipRanks’ Stock Analysis page.
